Pre-treatment integrase inhibitor resistance is uncommon in ART-naïve individuals with HIV-1 subtype A1 and D infections in Uganda

OBJECTIVE: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy (ART). However, prevalence data on natural resistance to integrase inhibitors (INSTIs) in circulating non-subtype B HIV-1 in sub-Saharan Africa is scarce. Our objective is to report prevalence of pre-trea...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:AIDS
Asıl Yazarlar: MCCLUSKEY, Suzanne M., KAMELIAN, Kimia, MUSINGUZI, Nicholas, KIGOZI, Simone, BOUM, Yap, BWANA, Mwebesa B., MUZOORA, Conrad, BRUMME, Zabrina L., CARRINGTON, Mary, CARLSON, Jonathan, FOLEY, Brian, HUNT, Peter W., MARTIN, Jeffrey N., BANGSBERG, David R., HARRIGAN, P. Richard, SIEDNER, Mark J., HABERER, Jessica E., LEE, Guinevere Q.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102316/
https://ncbi.nlm.nih.gov/pubmed/33635845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000002854
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller